Recently, our Curing NF team held their Vision Restoration Initiative (VRI) Annual Meeting, and our "Dream Team" of experts reported exciting new research to support the development of new therapies for NF patients experiencing vision loss.

The Gilbert Family Foundation today announced $23 million in grants to fund research projects as part of the organization’s Vision Restoration Initiative (VRI) and Brain Tumor Initiative (BTI).

Our Vision Restoration Initiative (VRI) awardees and their teams convened for our VRI Annual Meeting to discuss the results of their research projects focused on vision restoration therapies. Watch the video to learn more about the event and their findings.

The Gilbert Family Foundation is excited to welcome 28 researchers to our 2022 Vision Restoration Initiative (VRI) annual meeting. We will be discussing the latest breakthroughs in neurofibromatosis type 1 (NF1) optic pathway glioma and vision restoration research.

The Gilbert Family Foundation today announced funding of a new $5.4 million clinical study which aims to understand the mechanisms of vision loss caused by NF1-associated optic pathway gliomas, or NF1-OPGs.

The Gilbert Family Foundation today announced the launch of a clinical study that aims to validate optical coherence tomography (OCT) as a tool to objectively assess the visual system and its response to treatment in NF1 patients with optic pathway gliomas.

Optic pathway gliomas (OPGs) are slow-growing brain tumors that arise in or around the optic nerve and can cause the degeneration of the optic nerve and retinal ganglion cells (RGCs) leading to vision loss. GFF's Vision Restoration Initiative aims to develop new therapies to protect and restore vision for […]

Approximately 1 in 5 patients with neurofibromatosis type 1 (NF1) develop optic pathway gliomas (OPGs). These tumors can cause degeneration of the optic nerve and retinal ganglion cells (RGCs), ultimately leading to vision loss. GFF's Vision Restoration Initiative aims to develop neuroprotection/neuroenhancement therapies that protect and increase performance […]

The Gilbert Family Foundation is excited to announce the launch of its second research institutive to accelerate the development of therapies for neurofibromatosis type 1 (NF1). Around 1 in 5 NF1 patients develop optic pathway gliomas (OPGs) that cause degradation of the optic nerve and subsequent vision loss. […]